Skip to main content
NTLA logo

Intellia Therapeutics, Inc.

NTLANASDAQHealthcareBiotechnology

$11.16Today:- (-)1Y −56.89%

As of Oct 22, 2026 close

Market cap
$1.49B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$7.95$27.86
Volume (live)
-
Avg. volume (3M)
5.36M

Intellia Therapeutics, Inc. (NTLA) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Intellia Therapeutics, Inc. stock.

Analyst Consensus Rating

Investment consensus from 17 professional research analysts

Consensus Rating

Hold
Based on 17 unique analysts
(20 total ratings in last 90 days)
High Confidence3.0:1 Buy/Sell

Average Price Target

$19.50
+74.73% upside

Loading chart...

Strong Sell
Sell
Hold
Buy
Strong Buy

Latest NTLA Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Derek Archila
Wells Fargo
HoldMaintains
$15.00
Zacks Equity Research
Zacks Equity Research
HoldInitiates Coverage
-
Eliana Merle
Barclays
SellInitiates
$8.00
Unknown Analyst
Wells Fargo
HoldMaintains
$15.00
David Nierengarten
Wedbush
HoldMaintains
$12.00 → $13.00
Mitchell Kapoor
HC Wainwright
BuyReiterates
$25.00
Zacks Equity Research
Zacks Equity Research
HoldInitiates Coverage
-
Ekta Bagri
Zacks Equity Research
HoldInitiates Coverage
-
Joseph Thome
TD Cowen
BuyMaintains
-
Ahan Chakraborty
Zacks Equity Research
HoldInitiates Coverage
-
Debanjana Chatterjee
JonesTrading
BuyMaintains
$29.00
Terence Flynn
Morgan Stanley
HoldReiterates
$15.00
Whitney Ijem
Canaccord Genuity
BuyMaintains
$49.00
Salveen Richter
Goldman Sachs
SellMaintains
$9.00
Alec Stranahan
BofA Securities
HoldReiterates
$19.00 → $17.00
Jonathan Miller
Evercore ISI Group
BuyDowngrades
$16.00 → $24.00
Whitney Ijem
Canaccord Genuity
BuyMaintains
$49.00
Myles Minter
William Blair
BuyReiterates
-
Salveen Richter
Goldman Sachs
SellMaintains
$9.00
Luca Issi
RBC Capital
HoldMaintains
$15.00

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Oct 15, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for NTLA?

The analyst consensus rating for NTLA is Hold, based on the latest ratings from 17 analysts over the last 90 days.

What is the average price target for NTLA?

The average 12-month price target for NTLA is $19.50, representing an upside of 74.7% from the Oct 22, 2026 close of $11.16.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.